Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 16, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 22, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references an employee stock purchase plan
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001737329-26-000002
Filed / recorded
Jan 22, 2026, 5:53 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Jazz Pharmaceuticals plc
Issuer CIK
1232524
Ticker
JAZZ
Reporting person
Robert Iannone
Relationship
Officer
Officer title
EVP, Global Head of R&D & CMO
Security
Ordinary Shares
Table
Non-derivative (Table I)
Transaction date
Jan 16, 2026
Transaction code
A
Shares / units
11,699
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
84,398
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.
The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.